Ascendis Pharma A/S experienced a price increase of 5.04% during regular trading, crossing above its 5-day SMA. This movement comes as the Nasdaq-100 is up 0.37% and the S&P 500 has gained 0.60%, indicating a favorable market environment.
The stock's recent performance is attributed to optimism surrounding its pipeline and regulatory progress, despite a decline of 9.3% over the past week. Analysts have noted that Ascendis Pharma is undervalued by approximately 73.3%, with a projected intrinsic value of $748 per share, suggesting strong growth potential and a positive outlook for investors.
This upward movement reflects a broader trend in the market, as investors are increasingly optimistic about the company's future prospects, which may lead to further gains in the coming weeks.
Wall Street analysts forecast ASND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASND is 267.50 USD with a low forecast of 240.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast ASND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASND is 267.50 USD with a low forecast of 240.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 223.950
Low
240.00
Averages
267.50
High
325.00
Current: 223.950
Low
240.00
Averages
267.50
High
325.00
RBC Capital
Outperform
maintain
$245 -> $250
2026-01-20
Reason
RBC Capital
Price Target
$245 -> $250
AI Analysis
2026-01-20
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Ascendis Pharma to $250 from $245 and keeps an Outperform rating on the shares after meeting with its management team. On Yorvipath, Ascendis emphasizes that they anticipate that the launch momentum to continue in 2026 steadily, the analyst tells investors in a research note. Ascendis also notes that the market remains largely under penetrated in the U.S., discontinuation rate remains low, and the opportunity in the EU remains very meaningful, the firm added.
Wells Fargo
Derek Archila
Overweight
maintain
$322 -> $330
2026-01-20
Reason
Wells Fargo
Derek Archila
Price Target
$322 -> $330
2026-01-20
maintain
Overweight
Reason
Wells Fargo analyst Derek Archila raised the firm's price target on Ascendis Pharma to $330 from $322 and keeps an Overweight rating on the shares. The firm notes management's EUR 500M OCF guide excluding CNP implies EUR 1.1B-ERU 1.2B for Yorvipath and consistent with Ascendis' commentary of EUR 40M-EUR 50M in revenue growth quarter-over-quarter last week.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ASND
Unlock Now
Wells Fargo
Overweight
maintain
$297 -> $322
2026-01-09
Reason
Wells Fargo
Price Target
$297 -> $322
2026-01-09
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Ascendis Pharma to $322 from $297 and keeps an Overweight rating on the shares. The firm believes shares should trade up about 10% as the 52-week COACH data resets the bar higher in achondroplasia, with the combo likely to drive higher market share for TransCon CNP. Wells' estimates move up, and the TransCon CNP+Skytrofa combo is likely to become the standard of care over time.
Stifel
Alex Thompson
Buy
maintain
$254 -> $256
2025-12-11
Reason
Stifel
Alex Thompson
Price Target
$254 -> $256
2025-12-11
maintain
Buy
Reason
Stifel analyst Alex Thompson raised the firm's price target on Ascendis Pharma to $256 from $254 and keeps a Buy rating on the shares. The firm "refreshed diligence" on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.
About ASND
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
